Key facts
- Antiva Biosciences’s last known valuation is $123.0M.
- It has raised $144.8M across 4 recorded rounds; the latest was Early Stage VC ($38.5M) in Apr 2023.
- Notable investors include Mana Ventures, Gaingels, GV, University of California, Alexandria Venture Investments — 21 tracked in total.
- Antiva Biosciences has filed 6 Form Ds with the SEC since 2017, most recently Oct 2024 ($38.5M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Antiva Biosciences
Funding rounds
4 roundsAbout Antiva Biosciences
Developer of small molecule antivirals designed to improve health outcomes for patients suffering from diseases caused by HPV and other viruses. The company's antivirals are based on a medicinal chemistry platform that focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV, and animal retroviruses, enabling patients to recover from HPV-related diseases and other viruses.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2012
- Employees
- 26
- Website
- antivabio.com/
- Ownership
- Privately Held (backing)
Antiva Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antiva Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antiva Biosciences in its N-PORT filings yet. We sweep new filings monthly.